NCT05907382View on ClinicalTrials.gov

Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

PHASE1UnknownINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

March 31, 2024

Conditions

Safety and Tolerability

Interventions

DRUG

JMKX003002 will be administered orally

oral once

DRUG

JMKX003002 will be administered orally

oral once

DRUG

JMKX003002 will be administered orally

oral once

DRUG

Placebo in Cohorts 1 to 5

oral once

DRUG

Placebo in 2 Cohorts

oral once

Trial Locations (1)

Unknown

RECRUITING

Huashan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Jemincare

INDUSTRY

NCT05907382 - Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects | Biotech Hunter | Biotech Hunter